Oct 2026· DARU Journal of Pharmaceutical Sciences· Vol 34· 0 citations· 25 references
Medicine
TL;DR
Sodium oxybate significantly reduces EDS in narcolepsy with consistent effects across formulations and once-nightly and low-sodium formulations offer additional benefits in terms of dosing convenience and reduced sodium burden.
Melatonin shows promising but uncertain benefits for sleep disruptions in patients with malignancies, however, the evidence should be interpreted cautiously because of substantial clinical and statistical heterogeneity, limited sample sizes, short intervention durations, and predominantly subjective sleep measures.
Mohammad mehdi Abbasi, S. Pasha, F. Khosravi et al.· Current Reviews in Clinical...· 0 citations
OBJECTIVES
OFF episodes are a major source of disability in Parkinson disease (PD). Noninjectable apomorphine formulations, including inhaled (INH) and sublingual (SL) delivery systems, provide rapid dopaminergic stimulation for on-demand symptom relief. However, their efficacy and safety remain incompletely characteri...
Jamir Pitton Rissardo, J. L. Vargas Rojas, Juan Aristizabal Marin et al.· Clinical neuropharmacology· 0 citations
Evidence for EDS, insomnia symptoms, and RBD remains insufficient for definitive recommendations, and pooled estimates in these domains should not be over-interpreted given their very high statistical heterogeneity.
J. B. Canever, Laura Cechinel da Silva, Fernanda Samara Apio et al.· Journal of Neurology· 0 citations
Background: Sleep-related problems are common among patients receiving dialysis for end-stage renal disease (ESRD), while pharmacological management may be complicated by comorbidities, polypharmacy, and altered drug clearance. This systematic review and meta-analysis evaluated the effects of non-pharmacological interv...
Background Tourette syndrome is a neurodevelopmental disorder characterized by persistent motor and vocal tics. Dopamine D2 receptor antagonists can reduce tic severity but are frequently limited by metabolic, sedative, and extrapyramidal adverse effects. Ecopipam is a selective dopamine D1/D5 receptor antagonist with...
Aasim Ali, Abdullah Shahid, Muhammad Usman et al.· Therapeutic Advances in Psyc...· 0 citations
AIMS
Prucalopride, a 5-HT4 receptor agonist, has shown potential for rapid anxiolytic and antidepressant effects in preclinical studies. This meta-analysis aims to evaluate changes in anxiety and depressive symptoms after prucalopride treatment in chronically constipated adults.
METHODS
A systematic search of PubMed,...
Lucie Lebon, Denis J. David, M. Gasnier et al.· Psychiatry and Clinical Neur...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
